IMGT (XKRX:456570) Beginning Cash Position : ₩9,705.61 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is IMGT Beginning Cash Position?

IMGT's Beginning Cash Position for the quarter that ended in Dec. 2023 was ₩9,705.61 Mil.

IMGT's quarterly Beginning Cash Position increased from Dec. 2021 (₩421.11 Mil) to Dec. 2022 (₩3,312.14 Mil) and increased from Dec. 2022 (₩3,312.14 Mil) to Dec. 2023 (₩9,705.61 Mil).

IMGT's annual Beginning Cash Position increased from Dec. 2021 (₩421.11 Mil) to Dec. 2022 (₩3,312.14 Mil) and increased from Dec. 2022 (₩3,312.14 Mil) to Dec. 2023 (₩9,705.61 Mil).

IMGT Beginning Cash Position Historical Data

The historical data trend for IMGT's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Beginning Cash Position Chart

IMGT Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

474.13

421.11

3,312.14

9,705.61

IMGT Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Beginning Cash Position	474.13	421.11	3,312.14	9,705.61

IMGT Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

IMGT Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of IMGT's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

IMGT Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605

Website

http://www.imgt.co.kr

IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT Headlines

No Headlines